In Brief: Damon Labs indictments
This article was originally published in The Gray Sheet
Executive SummaryDamon Labs indictments: Justice Department indicts four former executives of Damon Clinical Laboratories on charges that they conspired to defraud Medicare of "over $25 mil.," according to a Jan. 22 release from the Office of the U.S. Attorney General. Charged are Joseph Isola, Beno Kon, William Thurston and Gerald Kullen. The indictment alleges that the four individuals were involved in a scheme while at Damon to defraud Medicare by adding the infrequently ordered serum ferritin test to a commonly ordered panel of blood chemistry tests, and the apolipoproteins test to a coronary risk profile panel. The indictment also charges that Isola, Kon and Thurston manipulated physician practice by dividing a common test panel for end-stage renal disease patients into two separate panels for which samples were taken on different days. In October 1996, Damon pleaded guilty to conspiracy to defraud Medicare and paid criminal and civil fines totaling $119 mil...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.